Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms22105123
Keywords
NK cells; PD-1; PD-L1; glucocorticoids; immunotherapy; cancer
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [21147, 19920, RC-2020 OPBG]
- Fondazione Umberto Veronesi fellowship
- AIRC
- European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [800924]
Ask authors/readers for more resources
Immune evasion is a crucial strategy adopted by tumor cells to promote survival and metastasis, with PD-1 playing a major role in inhibiting immune responses. Targeting the PD-1/PD-L1 axis has been a significant breakthrough in cancer treatment, representing unprecedented success in various cancer types. Further research on mechanisms regulating PD-1 expression and signaling in tumors is needed to improve therapeutic efficacy.
Immune evasion is a key strategy adopted by tumor cells to escape the immune system while promoting their survival and metastatic spreading. Indeed, several mechanisms have been developed by tumors to inhibit immune responses. PD-1 is a cell surface inhibitory receptor, which plays a major physiological role in the maintenance of peripheral tolerance. In pathological conditions, activation of the PD-1/PD-Ls signaling pathway may block immune cell activation, a mechanism exploited by tumor cells to evade the antitumor immune control. Targeting the PD-1/PD-L1 axis has represented a major breakthrough in cancer treatment. Indeed, the success of PD-1 blockade immunotherapies represents an unprecedented success in the treatment of different cancer types. To improve the therapeutic efficacy, a deeper understanding of the mechanisms regulating PD-1 expression and signaling in the tumor context is required. We provide an overview of the current knowledge of PD-1 expression on both tumor-infiltrating T and NK cells, summarizing the recent evidence on the stimuli regulating its expression. We also highlight perspectives and limitations of the role of PD-L1 expression as a predictive marker, discuss well-established and novel potential approaches to improve patient selection and clinical outcome and summarize current indications for anti-PD1/PD-L1 immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available